KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1636.86%.

  • Arbutus Biopharma's EBIT Margin fell 356700.0% to 1636.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 320.44%, marking a year-over-year increase of 9126200.0%. This contributed to the annual value of 1236.74% for FY2024, which is 8062000.0% down from last year.
  • Latest data reveals that Arbutus Biopharma reported EBIT Margin of 1636.86% as of Q3 2025, which was down 356700.0% from 13.86% recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's EBIT Margin peaked at 13.86% during Q2 2025, and registered a low of 1636.86% during Q3 2025.
  • In the last 5 years, Arbutus Biopharma's EBIT Margin had a median value of 648.66% in 2021 and averaged 723.96%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -11383800bps in 2024, then skyrocketed by 12643200bps in 2025.
  • Arbutus Biopharma's EBIT Margin (Quarter) stood at 648.66% in 2021, then skyrocketed by 44bps to 361.28% in 2022, then tumbled by -168bps to 967.23% in 2023, then increased by 8bps to 885.2% in 2024, then crashed by -85bps to 1636.86% in 2025.
  • Its EBIT Margin stands at 1636.86% for Q3 2025, versus 13.86% for Q2 2025 and 1456.86% for Q1 2025.